-
Mashup Score: 0Long-Term Outcomes from JAVELIN Bladder 100 - Cora Sternberg - 2 year(s) ago
Cora Sternberg joins Alicia Morgans in discussing subgroup analyses of the phase 3 JAVELIN Bladder 100 trial which demonstrated that first-line avelumab maintenance + best supportive care (BSC) significantly prolonged overall survival compared to BSC alone in patients with advanced urothelial carcinoma that had not progressed during initial induction treatment with platinum-based chemotherapy….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Long-Term Outcomes from JAVELIN Bladder 100 - Cora Sternberg - 2 year(s) ago
Cora Sternberg joins Alicia Morgans in discussing subgroup analyses of the phase 3 JAVELIN Bladder 100 trial which demonstrated that first-line avelumab maintenance + best supportive care (BSC) significantly prolonged overall survival compared to BSC alone in patients with advanced urothelial carcinoma that had not progressed during initial induction treatment with platinum-based chemotherapy….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Long-term outcomes from #JAVELIN Bladder 100. @cnsternberg @WCMEnglanderIPM joins @CaPsurvivorship @DanaFarber to discuss data presented at #ASCO22 examining subgroup analyses and long-term outcomes in a conversation on UroToday > https://t.co/wCyXr5GKJU https://t.co/eApu8Zabqk
-
-
Mashup Score: 4
ESMO 2022 extended results of JAVELIN Bladder 100, patients receiving less than 12 months of Avelumab first-line maintenance for advanced urothelial carcinoma, Avelumab first-line maintenance + best supportive care.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Avelumab first-line maintenance for advanced #UrothelialCarcinoma: results from patients with ≥12 months of treatment in #JAVELIN Bladder 100. Presentation by Jeanny Aragon-Ching, MD @InovaSchar. #ESMO22 coverage by @zklaassen_md @GACancerCenter > https://t.co/FM6bcCRll5 @myESMO https://t.co/90qMkI8KYh
-
-
Mashup Score: 0Long-Term Outcomes from JAVELIN Bladder 100 - Cora Sternberg - 2 year(s) ago
Cora Sternberg joins Alicia Morgans in discussing subgroup analyses of the phase 3 JAVELIN Bladder 100 trial which demonstrated that first-line avelumab maintenance + best supportive care (BSC) significantly prolonged overall survival compared to BSC alone in patients with advanced urothelial carcinoma that had not progressed during initial induction treatment with platinum-based chemotherapy….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Long-term outcomes from the #JAVELIN Bladder 100 trial. @cnsternberg @WCMEnglanderIPM discusses here! #FullVideo > https://t.co/WksJOF858v. Coverage of 1760P - ≥12 mo of treatment in JAVELIN Bladder 100 by Dr. Jeanny Aragon-Ching tomorrow on UroToday! @PfizerOncMed #ESMO22 https://t.co/seJvqUDMeL
-
-
Mashup Score: 0Long-Term Outcomes from JAVELIN Bladder 100 - Cora Sternberg - 2 year(s) ago
Cora Sternberg joins Alicia Morgans in discussing subgroup analyses of the phase 3 JAVELIN Bladder 100 trial which demonstrated that first-line avelumab maintenance + best supportive care (BSC) significantly prolonged overall survival compared to BSC alone in patients with advanced urothelial carcinoma that had not progressed during initial induction treatment with platinum-based chemotherapy….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Long-term outcomes from #JAVELIN Bladder 100. Here, @cnsternberg @WCMEnglanderIPM and @CaPsurvivorship @DanaFarber discuss subgroup analyses relevant to the clinic on UroToday. #FullVideo > https://t.co/s8uJ7XZsja @PfizerOncMed New data to be released at #ESMO22! https://t.co/YGAVRuPeCm
-
-
Mashup Score: 1
ESMO 2022 enomic biomarkers in peripheral blood from patients enrolled in the JAVELIN Bladder 100 trial of avelumab first-line maintenance in advanced urothelial carcinoma
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Genomic biomarkers in peripheral blood from patients enrolled in the #JAVELIN Bladder 100 trial of avelumab first-line maintenance in advanced #UrothelialCarcinoma. Presented by @tompowles1 @QMBCI. #ESMO22 written coverage by @zklaassen_md > https://t.co/NynbSAigjp @myESMO https://t.co/XnxsXVdW5h
-
-
Mashup Score: 0Long-Term Outcomes from JAVELIN Bladder 100 - Cora Sternberg - 2 year(s) ago
Cora Sternberg joins Alicia Morgans in discussing subgroup analyses of the phase 3 JAVELIN Bladder 100 trial which demonstrated that first-line avelumab maintenance + best supportive care (BSC) significantly prolonged overall survival compared to BSC alone in patients with advanced urothelial carcinoma that had not progressed during initial induction treatment with platinum-based chemotherapy….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Long-term outcomes from the #JAVELIN Bladder 100 trial. @cnsternberg @WCMEnglanderIPM discusses study design and subgroup analyses showing long-term outcomes data. #FullVideo > https://t.co/WksJOF858v Looking forward to #ESMO22 presentations this weekend! @PfizerOncMed https://t.co/6SFDc0lEvh
-
-
Mashup Score: 0Long-Term Outcomes from JAVELIN Bladder 100 - Cora Sternberg - 2 year(s) ago
Cora Sternberg joins Alicia Morgans in discussing subgroup analyses of the phase 3 JAVELIN Bladder 100 trial which demonstrated that first-line avelumab maintenance + best supportive care (BSC) significantly prolonged overall survival compared to BSC alone in patients with advanced urothelial carcinoma that had not progressed during initial induction treatment with platinum-based chemotherapy….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Long-term outcomes from #JAVELIN Bladder 100. Here, @cnsternberg @WCMEnglanderIPM and @CaPsurvivorship @DanaFarber discuss subgroup analyses relevant to the clinic on UroToday. #FullVideo > https://t.co/s8uJ7XZsja @PfizerOncMed New data to be released at #ESMO22! https://t.co/T59NdNNFKr
-
-
Mashup Score: 0Long-Term Outcomes from JAVELIN Bladder 100 - Cora Sternberg - 2 year(s) ago
Cora Sternberg joins Alicia Morgans in discussing subgroup analyses of the phase 3 JAVELIN Bladder 100 trial which demonstrated that first-line avelumab maintenance + best supportive care (BSC) significantly prolonged overall survival compared to BSC alone in patients with advanced urothelial carcinoma that had not progressed during initial induction treatment with platinum-based chemotherapy….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Long-term outcomes from the #JAVELIN Bladder 100 trial. @cnsternberg @WCMEnglanderIPM discusses study design and subgroup analyses showing long-term outcomes data. #FullVideo > https://t.co/WksJOF8CY3 Looking forward to #ESMO22 presentations this weekend! @PfizerOncMed https://t.co/LxA7FYy3MX
-
-
Mashup Score: 0Long-Term Outcomes from JAVELIN Bladder 100 - Cora Sternberg - 2 year(s) ago
Cora Sternberg joins Alicia Morgans in discussing subgroup analyses of the phase 3 JAVELIN Bladder 100 trial which demonstrated that first-line avelumab maintenance + best supportive care (BSC) significantly prolonged overall survival compared to BSC alone in patients with advanced urothelial carcinoma that had not progressed during initial induction treatment with platinum-based chemotherapy….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Long-term outcomes from #JAVELIN Bladder 100. @cnsternberg @WCMEnglanderIPM joins @CaPsurvivorship @DanaFarber to discuss data presented at #ASCO22 examining subgroup analyses and long-term outcomes in a conversation on UroToday > https://t.co/wCyXr5GKJU https://t.co/V9yKZZtLdC
-
Long-term outcomes from #JAVELIN Bladder 100. @cnsternberg @WCMEnglanderIPM joins @CaPsurvivorship @DanaFarber to discuss data presented at #ASCO22 examining subgroup analyses and long-term outcomes in a conversation on UroToday > https://t.co/wCyXr5GKJU https://t.co/dN5JWrAdr3